BIOKÉ Webshop

Forgot password?Login

No need to login to view prices!

No account?

Enjoy the advantages of a BIOKÉ webshop account.

Invalid login

Your credentials are incorrect or you are trying to login with a non-existing webshop account. Our website shows product prices without login! Therefore webshop accounts that were only used to view prices have been deleted.

Please create a new account with your shipping and billing details if you would like to be able to order or view your discount.


Webshop under construction

The BIOKÉ webshop is closed until January 2nd, 2019. We wish you a successful 2019!

Forgot your password?

Don't worry. Enter your username and we will send you a link to reset your password if an associated user is found.

{* passlost_errormessage *}

Need help?

Have trouble resetting your password? Contact us and we will help you.

You've got mail

You will receive an e-mail containing a link to start the recovery procedure within minutes.


Change password

Change your password to something secure.

Success

Your password has been changed.


Password sent

You will receive an e-mail from us containing your new password in the coming minutes.

Please change your password to something memorable and secure upon logging in.


{* error_message *}

Welcome

Sign out

Clinical trial of TNF-α antagonist for severe cutaneous adverse reactions uses the NovoCyte®


Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions (SCARs) involving keratinocyte apoptosis and detachment of the epidermis. Current treatments, which include the use of corticosteroids, are controversial in their effectiveness. Numerous studies have demonstrated that the mechanism of SJS-TEN involves effector cytotoxic T lymphocytes (CTLs). In addition, treatment with anti–TNF-α biologic agents appears to be beneficial in patients with TEN and TEN-like acute cutaneous lupus erythematosus. However a randomized, systemic trial had not yet been run. 

Investigators Wang et al. address this issue in a clinical trial published in a current issue of the Journal of Clinical investigation. The authors concluded that the anti–TNF-α biologic agent etanercept is an effective alternative treatment for CTL-mediated SCARs. In comparison with conventional systemic corticosteroids, etanercept showed a shorter skin-healing time for patients with moderate-to-severe CTL-mediated SCARs, with a lower incidence of GI side effects. 

In the article, the researchers used the NovoCyte flow cytometer from ACEA Biosciences to determine the frequency of regulatory T cells (Treg cells) in patients after treatment with either Etanercept or Corticosteroid (Figure below). Treg cells (identified as CD4+CD25hiFoxp3+) were measured in patient’s blood at various stages of the illness. It was determined that entanercept but not corticosteroid treatment increased Treg cell populations, identifying a possible mechanism of action by which entabercept may help ameliorate the disease. In conclusion, this study may provide a rationale for the clinical application of anti–TNF-α biologic agents in the treatment of patients with CTL-mediated SCARs.

 


Immunological effects in SJS-TEN patients with 10% or greater BSA detachment after etanercept or corticosteroid treatment. Figures adapted from J Clin Invest. 2018 Feb 5. pii: 93349. doi: 10.1172/JCI93349.

Product has been added to your cart.